Open Access

Compliance By Architecture: A Human-AI Operating Model For Medical Inquiry Management Conceptual Framework Paper

4 Independent Researcher, USA

Abstract

Medical Information functions are exploring artificial intelligence (AI) and advanced analytics to improve the speed, consistency, scalability, and intelligence of Medical Inquiry management. Generative AI can support intake, information extraction, classification, scientific-content retrieval, evidence synthesis, response drafting, documentation, and analytics. These opportunities arise within a controlled environment in which scientific accuracy, response scope, source traceability, privacy, safety reporting, product-quality escalation, documentation, and human accountability are essential. This paper proposes Compliance by Architecture: a practitioner-informed model in which controls are embedded across the complete inquiry pathway rather than concentrated at a final review gate. The framework was developed through a practitioner-informed conceptual synthesis of professional Medical Information guidance, peer-reviewed literature, pharmacovigilance and electronic-record requirements, and responsible-AI principles and frameworks. The model comprises seven interconnected layers: channels and intake; identity, context, and reference data; governed scientific content and knowledge; AI orchestration and retrieval; workflow, routing, and the system of record; analytics and monitoring; and human decision and accountability. It also introduces an automation boundary that distinguishes AI-accelerated activities, human-reviewed activities, and human-owned decisions or escalations. The framework integrates established Medical Information practice, pharmacovigilance expectations, electronic-record controls where applicable, and responsible-AI principles while remaining explicitly conceptual rather than regulator-issued. Its intended contribution is a practical architecture for deploying AI as a governed scientific-workflow capability, not as an autonomous scientific authority. Future empirical work should test the framework across jurisdictions, inquiry types, content models, and human-AI workflows.

Keywords

References

Medical Affairs Professional Society; Medical Information Leaders in Europe; Pharma Collaboration for Transparent Medical Information. Essential elements of a best-in-class Medical Information organization: standards and guidance. 2021. Available from: https://www.mile-association.org/wp-content/uploads/2023/06/MedInfo-SG-2022-12-1.pdf
Albano D, Pragga F, Rai R, Flowers T, Parmar P, Wnorowski S, et al. The Medical Information scientific process: Define, Research, Evaluate, Synthesize, and Share (DRESS). Ther Innov Regul Sci. 2022;56(3):405-414. doi:10.1007/s43441-021-00366-w.
Hermes-DeSantis ER, Johnson RM, Redlich A, et al. Proposed best practice guidelines for scientific response documents: a consensus statement from phactMI. Ther Innov Regul Sci. 2020;54(6):1303-1311. doi:10.1007/s43441-020-00151-1.
Wnorowski S, Niemoller F, Glaetzer A, Tamburri R, Vine E, Flick F, et al. Best practices for Medical Information global response documents from phactMI and MILE. Pharm Med. 2026;40:87-94. doi:10.1007/s40290-025-00598-3.
Guillot P, Shea J, Shoemaker S, Rocco M, DeLuca M, Rai R, Hermes-DeSantis ER. Medical Information delivering improved customer experience: a guide. Pharm Med. 2023;37(2):111-119. doi:10.1007/s40290-023-00469-9.
World Health Organization. Ethics and governance of artificial intelligence for health: guidance on large multi-modal models. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240084759
National Institute of Standards and Technology. Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile. NIST AI 600-1. Gaithersburg (MD): NIST; 2024. doi:10.6028/NIST.AI.600-1.
National Institute of Standards and Technology. Artificial Intelligence Risk Management Framework (AI RMF 1.0). NIST AI 100-1. Gaithersburg (MD): NIST; 2023. doi:10.6028/NIST.AI.100-1.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products. Rev 2. 2017. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf
Electronic Code of Federal Regulations. Title 21, Β§314.80: Postmarketing reporting of adverse drug experiences. Current electronic edition. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.80
US Food and Drug Administration. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products. Draft guidance for industry and other interested parties. January 2025. Available from: https://www.fda.gov/media/184830/download
European Medicines Agency. Reflection paper on the use of artificial intelligence in the medicinal product lifecycle. EMA/CHMP/CVMP/83833/2023. Adopted September 2024. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
Electronic Code of Federal Regulations. Title 21, Part 11: Electronic records; electronic signatures. Current electronic edition. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
Electronic Code of Federal Regulations. Title 45, Β§164.312: Technical safeguards. Current electronic edition. Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-C/section-164.312

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >> 

Similar Articles

21-30 of 34

You may also start an advanced similarity search for this article.